Navigation Links
FDA Issues Complete Response Letter for Iclaprim
Date:1/19/2009

REINACH Switzerland, January 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announces today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI). The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy in order to gain approval.

President and CEO Dr Jurgen Raths commented: "After the negative recommendation of the Advisory Committee of last November, the FDA opinion comes as no surprise. We now aim to develop a viable roadmap to approval in close consultation with the FDA. The drastic cost saving measures that we've recently implemented should buy us sufficient time to consider and develop strategic options for progressing iclaprim's development."

In its letter to Arpida, the FDA stated the Company's NDA did not demonstrate the efficacy of iclaprim for treatment of cSSSI within an acceptable non-inferiority margin. The FDA requires additional data to assess the benefits and risks of iclaprim for cSSSI.

To address this deficiency, the FDA requests an additional study or studies to demonstrate effectiveness of iclaprim. An additional study showing non-inferiority of iclaprim to an approved comparator may be sufficient to meet this requirement, depending on the study results.

Moreover, the FDA raised questions related to the drug product, which Arpida believes can be rapidly addressed. In addition, the resubmission should provide updated safety data and labelling information.

Arpida today also announces that the restructuring that was announced late last year, is progressing as planned. In addition, the Board of Directors has decided to decrease its membership
'/>"/>

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
4. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
5. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
6. FDA Issues Draft Guidance on Priority Review Vouchers
7. Resverlogix Issues a Management Statement
8. SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Arbitration Panel Issues Ruling in Distribution Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: IPXL).  Such investors are advised to contact ... 888-476-6529, ext. 237. The investigation concerns whether ... violated Sections 10(b) and 20(a) of the Securities Exchange ... 2014, Impax Laboratories, Inc. (the "Company") issued a press ...
(Date:7/29/2014)... 29, 2014 According to the ... Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud ... & Trends to 2018", published by MarketsandMarkets, analyzes and ... such as North America , ... and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, applauds the Editorial ... a strong position in opposition to current federal ... 2014 publication.  The New York Times also announces ... week exploring the issue called "High Time:  An ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... First Capability To Rapidly Identify Five Candida ... Positive Blood Cultures In One Test, WOBURN, ... FDA 510(k) clearance of the Yeast Traffic Light ... positive blood cultures. The,Yeast Traffic Light(TM) is the ...
... 23 Affitech AS, the Norwegian human,antibody ... accomplished the,second milestone in its research and ... recombinant antibodies against an unnamed oncology,target. Affitech ... Antibody,Screening) system that included its proprietary antibody ...
... 22, 2008 -- Chemists at Rice University have discovered ... tiny, wand-like nanoparticles that are being studied in dozens ... disease and improving electronic viewscreens. , "The content of ... is only about 20 percent," said lead researcher Eugene ...
Cached Biology Technology:AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2Purifying nanorods: Big success with tiny cleanup 2
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the ... of researchers including the labs headed by Professors Neelima ... of Plant Biology. The new genome information may help ... published July 27 in the journal Nature Genetics ... Aachen University in Germany. The UC Davis labs carried ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... buzzing around your plate. Its color and motion could both influence ... might decide it was a bee and move away. Conversely, you ... insect away. You perceive both color and motion, and decide based ... heartbeat. The mystery is how. In an article published November ...
... A human clinical study of older adults has demonstrated ... dietary supplement created by Natura Therapeutics, Inc., showed ... individuals taking a placebo. Cognition includes processes such as ... The company,s study, Nutraceutical Intervention Improves Older Adults, Cognitive ...
... early infancy may be a key to early identification of ... of Mental Health (NIMH), part of the National Institutes of ... the study reveals the earliest sign of developing autism ever ... first two to six months of life. "Autism ...
Cached Biology News:Stanford researchers surprised to find how neural circuits identify information needed for decisions 2Stanford researchers surprised to find how neural circuits identify information needed for decisions 3Stanford researchers surprised to find how neural circuits identify information needed for decisions 4Stanford researchers surprised to find how neural circuits identify information needed for decisions 5Natura Therapeutics product shown to improve decision making skills in older adults 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human LAIR2 Biotinylated Affinity Purified PAb...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: